Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Emergent BioSolutions (EBS) Misses Q1 EPS by 1c, Reaffirms Guidance
May 4, 2017 4:52 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $116.17 million.
Emergent BioSolutions reaffirmed guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More